Drug Search Results
More Filters [+]

Raclopride

Alternative Names: raclopride, meglitinides
Latest Update: 2024-10-14
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: D2 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Raclopride

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Bulimia Nervosa|Anorexia|Malnutrition|Substance Abuse Unspecified

Phase 2: Healthy Volunteers|Parkinson's Disease

Phase 1: Opioid-Related Disorders|Depressive Disorder|Obesity|Overweight|Traumatic Brain Injury

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

17-AA-0114

P1

Recruiting

Opioid-Related Disorders

2025-12-31

NCT03999190

N/A

Withdrawn

Schizophrenia

2025-07-01

14-N-0083

P1

Completed

Traumatic Brain Injury

2024-02-13

18-DK-0132

P1

Completed

Overweight|Obesity

2022-03-31

Recent News Events